Overview and Scope
Atrial fibrillation refers to a disorder of the heart caused by an abnormality in the normal sequence of electrical impulses that changes the rate or rhythm at which the heart beats and begins in the heart's upper chambers (atria). Electrical impulses can be too fast, too slow, or erratically occurring, resulting in irregular heartbeats.

Sizing and Forecast
The atrial fibrillation market size has grown rapidly in recent years. It will grow from $12.02 billion in 2023 to $13.47 billion in 2024 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to increasing awareness and screening programs, technological innovations in treatment, increasing healthcare expenditure, clinical research and drug development, genetic predisposition..

The atrial fibrillation market size is expected to see rapid growth in the next few years. It will grow to $21.66 billion in 2028 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to focus on stroke prevention, patient and physician education programs, global initiatives for cardiovascular health, increasing electrophysiology procedures, customization of treatment plans, government initiatives for cardiovascular disease prevention.. Major trends in the forecast period include advancements in diagnostic technologies, rise in the incidence of atrial fibrillation, advancements in catheter ablation techniques, emergence of novel oral anticoagulants (noacs), integration of wearable technologies for monitoring, expanding role of telemedicine in af management, advancements in implantable devices..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/atrial-fibrillation-global-market-report

Segmentation & Regional Insights
The atrial fibrillation market covered in this report is segmented –

1) By Type: Surgical, Non-Surgical
2) By Technology: Radiofrequency, Laser, Cryotherapy, Other Technologies
3) By Treatment Type: Pharmacological Treatment, Non-pharmacological Treatment, Maze Surgery, Electric Cardioversion
4) By End User: Hospitals, Electrophysiology Labs, Ambulatory Surgical Centers

North America was the largest region in the atrial fibrillation market in 2023. Asia-Pacific is expected to be the fastest-growing region in the atrial fibrillation market report forecast period. The regions covered in the atrial fibrillation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8007&type=smp

Major Driver Impacting Market Growth
The increase in the geriatric population is expected to drive the atrial fibrillation market forward. The geriatric population refers to adults 65 and older who are more likely to fall due to various factors, such as postural hypotension and balance or gait problems. Age factor and conduction disturbances are present on the surface electrocardiogram before AF onset in most geriatric patients. For instance, in October 2022, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations responsible for international public health, six people in the world will be aged 60 years or older by 2030. At this point, there will be 1.4 billion people, up from 1 billion in 2020, who are 60 years of age or older. The number of individuals 60 and older in the world will double (to 2.1 billion) by the year 2050. Between 2020 and 2050, there will be 426 million more people who are 80 years of age or older than there are today. Therefore, the growing geriatric population is driving the growth of the atrial fibrillation market.

Key Industry Players
Major companies operating in the atrial fibrillation market report are AtriCure Inc., Johnson & Johnson Private Limited, Abbott Laboratories, C.H. Boehringer Sohn AG & Co. KG, Biotronik Se & Co. Kg, Boston Scientific Corporation, Bristol-Myers Squibb Company, CardioFocus Inc., Sanofi S.A, Medtronic plc, Biosense Webster Inc., MicroPort Scientific Corporation, Siemens AG, Acutus Medical Inc., AEGEA Medical Inc., Apama Medical Inc., Aria CV Inc., Armetheon Inc., BioSig Technologies Inc., Cardialen Inc., CardioRobotics Inc., CardioInsight Technologies Inc., Circa Scientific LLC, CorWave SA, EpiEP Inc., Farapulse Inc., Fibralign Corporation, Impulse Dynamics NV, JenaValve Technology Inc., Kardium Inc.

The atrial fibrillation market report table of contents includes:


1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis


Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model